Insufficient Evidence to Recommend Shu Mian Capsule in Managing Depression With or Without Comorbid Insomnia: A Systematic Review With Meta-Analysis and Trial Sequential Analysis DOI Creative Commons

Fei-Yi Zhao,

Peijie Xu, Gerard A. Kennedy

et al.

Neuropsychiatric Disease and Treatment, Journal Year: 2025, Volume and Issue: Volume 21, P. 167 - 183

Published: Jan. 1, 2025

This systematic review with trial sequential analysis (TSA) aims to evaluate the efficacy and safety of Shu Mian Capsule (SMC), a commercial Chinese polyherbal preparation, for managing depression or without comorbid insomnia. Controlled clinical trials assessing SMC against waitlist control, placebo active controls, as an adjunct treatment were searched across seven databases. Risk bias evidence quality assessed using Cochrane criteria GRADE framework, respectively. Fourteen studies analyzed, involving 1207 participants. Trials comparing standard antidepressive treatments limited. In depressed patients insomnia, combining antidepressants reduced incidence antidepressants-induced sleep disorders (from 12.2% 3.8%) but did not significantly lower Hamilton Rating Scale Depression (HAM-D) scores compared alone [SMD = -0.09, 95% CI (-0.32, 0.14), p 0.45]. combination psychotropic drugs HAM-D -1.29, (-1.96, -0.62), < 0.01] Pittsburgh Sleep Quality Index -1.53, (-1.95, -1.11), 0.01], exhibited various drug-related adverse effects alone. TSA validated sample size adequacy; nevertheless, methodological supporting varied from very low due substantial risk. Additionally, 92.9% lacked follow-ups. The effectiveness alternative conventional is unclear. For adding care demonstrates augmented improved safety, though methodologically Further rigorous are warranted confirm SMC's short-term explore its medium- long-term either complementary therapy. Current precludes recommendations administration in depression.

Language: Английский

An upconversion nanoplatform based multi-effective theatment for Parkinson’s disease DOI

Binbin Hu,

Huaqiang Fang, Zhixin Huang

et al.

Chemical Engineering Journal, Journal Year: 2023, Volume and Issue: 465, P. 142959 - 142959

Published: April 13, 2023

Language: Английский

Citations

13
Efficacy of ginsenoside Rg1 on rodent models of depression: A systematic review and meta-analysis DOI
Yating Wang, Xiaole Wang, Lei Lan

et al.

Psychopharmacology, Journal Year: 2024, Volume and Issue: unknown

Published: July 23, 2024

Language: Английский

Citations

5
Paeoniflorin Ameliorates Skeletal Muscle Atrophy in Chronic Kidney Disease via AMPK/SIRT1/PGC-1α-Mediated Oxidative Stress and Mitochondrial Dysfunction DOI Creative Commons
Qiang Li, Jing Wu, Jiawen Huang

et al.

Frontiers in Pharmacology, Journal Year: 2022, Volume and Issue: 13

Published: March 8, 2022

Skeletal muscle atrophy is a common and serious complication of chronic kidney disease (CKD). Oxidative stress mitochondrial dysfunction are involved in the pathogenesis atrophy. The aim this study was to explore effects mechanisms paeoniflorin on CKD skeletal We demonstrated that significantly improved renal function, calcium/phosphorus disorders, nutrition index 5/6 nephrectomized model rats. Paeoniflorin ameliorated expression proteins associated with differentiation, including F-box (MAFbx/atrogin-1), RING finger 1 (MuRF1), MyoD myogenin (MyoG). In addition, modulated redox homeostasis by increasing antioxidant activity suppressing excessive accumulation reactive oxygen species (ROS). alleviated activities electron transport chain complexes membrane potential. Furthermore, also regulates dynamics. Importantly, upregulated silent information regulator (SIRT1), peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α), phosphorylation AMP-activated protein kinase (AMPK). Similar results were observed C2C12 myoblasts treated TNF-α paeoniflorin. Notably, these beneficial abolished inhibiting AMPK SIRT1 knocking down PGC-1α. Taken together, showed for first time has great therapeutic potential through AMPK/SIRT1/PGC-1α-mediated oxidative dysfunction.

Language: Английский

Citations

20
Niuhuang Qingxin Wan ameliorates depressive-like behaviors and improves hippocampal neurogenesis through modulating TrkB/ERK/CREB signaling pathway in chronic restraint stress or corticosterone challenge mice DOI Creative Commons

Qiaohui Du,

Chong Gao, Bun Tsoi

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 14

Published: Jan. 11, 2024

Introduction: Chronic stress-associated hormonal imbalance impairs hippocampal neurogenesis, contributing to depressive and anxiety behaviors. Targeting neurogenesis is thus a promising antidepressant therapeutic strategy. Niuhuang Qingxin Wan (NHQXW) an herbal formula for mental disorders in Traditional Chinese Medicine (TCM) practice, but its anti-depressant efficacies mechanisms remain unverified. Methods: In the present study, we tested hypothesis that NHQXW could ameliorate depressive-like behaviors improve by modulating TrkB/ERK/CREB signaling pathway utilizing two depression mouse models including chronic restraint stress (CRS) model corticosterone (CORT) (CCS) induced model. The depression-like were orally treated with whereas fluoxetine was used as positive control group. We evaluated effects of on depressive- anxiety-like determined inducing neurogenesis. Results: treatment significantly ameliorated those models. improved CRS mice CCS mice. potential neurogenic mechanism identified regulating expression levels BDNF, TrkB, p-ERK (T202/T204), p-MEK1/2 (S217/221), p-CREB (S133) hippocampus area revealed similar fluoxetine. Moreover, long-term preventing withdrawal-associated rebound symptoms Furthermore, bioactivity-guided quality liquiritin one bioactive compounds bioactivities neurogenesis-promoting effects. Discussion: Taken together, be TCM attenuate against depression. underlying correlated activities stimulating pathway.

Language: Английский

Citations

4
Insufficient Evidence to Recommend Shu Mian Capsule in Managing Depression With or Without Comorbid Insomnia: A Systematic Review With Meta-Analysis and Trial Sequential Analysis DOI Creative Commons

Fei-Yi Zhao,

Peijie Xu, Gerard A. Kennedy

et al.

Neuropsychiatric Disease and Treatment, Journal Year: 2025, Volume and Issue: Volume 21, P. 167 - 183

Published: Jan. 1, 2025

This systematic review with trial sequential analysis (TSA) aims to evaluate the efficacy and safety of Shu Mian Capsule (SMC), a commercial Chinese polyherbal preparation, for managing depression or without comorbid insomnia. Controlled clinical trials assessing SMC against waitlist control, placebo active controls, as an adjunct treatment were searched across seven databases. Risk bias evidence quality assessed using Cochrane criteria GRADE framework, respectively. Fourteen studies analyzed, involving 1207 participants. Trials comparing standard antidepressive treatments limited. In depressed patients insomnia, combining antidepressants reduced incidence antidepressants-induced sleep disorders (from 12.2% 3.8%) but did not significantly lower Hamilton Rating Scale Depression (HAM-D) scores compared alone [SMD = -0.09, 95% CI (-0.32, 0.14), p 0.45]. combination psychotropic drugs HAM-D -1.29, (-1.96, -0.62), < 0.01] Pittsburgh Sleep Quality Index -1.53, (-1.95, -1.11), 0.01], exhibited various drug-related adverse effects alone. TSA validated sample size adequacy; nevertheless, methodological supporting varied from very low due substantial risk. Additionally, 92.9% lacked follow-ups. The effectiveness alternative conventional is unclear. For adding care demonstrates augmented improved safety, though methodologically Further rigorous are warranted confirm SMC's short-term explore its medium- long-term either complementary therapy. Current precludes recommendations administration in depression.

Language: Английский

Citations

0